Skip to content

Press Release Details

Haemonetics 3rd Quarter Fiscal 2018 Earnings Release Available on Investor Relations Website

Feb 6, 2018
Financial release accessible online

BRAINTREE, Mass., Feb. 6, 2018 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that third quarter and year-to-date fiscal 2018 financial results are available on its Investor relations website.

HAE logo April 2016.

The Company is posting this press release and, additionally, results tables that will be referenced on its webcast to its Investor Relations website. 

Direct link to Earnings Release 3Q and YTD FY18:

https://haemonetics.gcs-web.com/static-files/d6804db2-5ec8-4d4a-8101-de58da81b57c

Direct link to Results Tables 3Q and YTD FY18 That Will Be Referenced on Webcast:

https://haemonetics.gcs-web.com/static-files/4567ceb1-882e-408e-9a8b-7bf490e0b8ad

As previously announced, the Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on February 6, 2018. A live webcast of the call can be accessed on Haemonetics' investor relations website.

Direct link to Conference Call Webcast: https://edge.media-server.com/m6/p/qyrbnnof.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com

 

Investor contact:  

Media Contact:

Gerry Gould, VP-Investor Relations  

Carla Burigatto, VP-Communications

(781) 356-9402     

(781) 348-7263

gerry.gould@haemonetics.com   

carla.burigatto@haemonetics.com

 

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/haemonetics-3rd-quarter-fiscal-2018-earnings-release-available-on-investor-relations-website-300593645.html

SOURCE Haemonetics Corporation